Immunitybio

Yahoo Finance • 2 days ago

INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit– Hagens Berman

SAN FRANCISCO, April 10, 2026 (GLOBE NEWSWIRE) -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19,... Full story

Yahoo Finance • 2 days ago

ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX

NEW YORK, April 10, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive... Full story

Yahoo Finance • 2 days ago

DEADLINE ALERT for SMCI, IBRX, and PINS: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

LOS ANGELES, April 10, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the... Full story

Yahoo Finance • 2 days ago

IBRX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in ImmunityBio, Inc. Securities Lawsuit — The Gross Law Firm

NEW YORK, April 10, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of ImmunityBio, Inc. (NASDAQ: IBRX). Shareholders who purchased shares of IBRX during the class period listed are encouraged to... Full story

Yahoo Finance • 3 days ago

DEADLINE ALERT for ATRA, COTY, SMCI, IBRX: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

BENSALEM, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the... Full story

Yahoo Finance • 3 days ago

ImmunityBio reports Q1 results

* ImmunityBio press release [https://seekingalpha.com/pr/20467404-immunitybio-reports-net-product-revenue-increased-nearly-2_7-times-year-over-year-to-record] (IBRX [https://seekingalpha.com/symbol/IBRX]): Q1 revenue of $44.2M beats by $... Full story

Yahoo Finance • 5 days ago

ImmunityBio, Inc. Class Action Lawsuit Seeks Recovery for Investors; May 26, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP

Did you buy IBRX securities between January 19, 2026, and March 24, 2026? Affected IBRX Investor Summary Who: ImmunityBio, Inc. (NASDAQ: IBRX)What: Securities fraud class action lawsuit filedClass Period: January 19, 2026 through March 2... Full story

Yahoo Finance • 5 days ago

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES, April 07, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. (“ImmunityBio” or “the Company”) (NASDAQ: IBRX) for... Full story

Yahoo Finance • 6 days ago

ImmunityBio, Inc. (IBRX) Facing Securities Class Action Amid FDA Warning Regarding Unsupported Cancer Treatment Claims, $2 Billion Market Capitalization Wiped Out -- Hagens Berman

SAN FRANCISCO, April 06, 2026 (GLOBE NEWSWIRE) -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19,... Full story

Yahoo Finance • 6 days ago

IBRX INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

SAN DIEGO, April 06, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities between January 19, 2026 and March 24, 2026, inclusive (... Full story

Yahoo Finance • 7 days ago

Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

NEW YORK, April 05, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against ImmunityBio, Inc. (NASDAQ: IBRX) and certain... Full story

Yahoo Finance • 10 days ago

IBRX SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of ImmunityBio, Inc. Investors - Contact Kirby McInerney LLP by May 26, 2026

NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ:IBRX) securities to contact Lauren Molinaro of Kirby McInerney LLP by email at in... Full story

Yahoo Finance • 10 days ago

ImmunityBio, Inc. (IBRX) Faces Securities Class Action Amid FDA Warning Regarding Unsupported Cancer Treatment Claims, $2 Billion Market Capitalization Wiped Out -- Hagens Berman

SAN FRANCISCO, April 02, 2026 (GLOBE NEWSWIRE) -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19,... Full story

Yahoo Finance • 12 days ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX

NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX).   Such investors are advised to contact Danielle P... Full story

Yahoo Finance • 12 days ago

Jim Cramer on ImmunityBio: “I Would Encourage You to Own It, Provided You Don’t Own Any Other Spec”

Jim Cramer gave top insight on ImmunityBio, Inc. (NYSE:IBRX), sharing a game plan of what to buy, sell, and hold right now. When a caller mentioned that they have a small position in the stock, Cramer commented: Okay, that is a pure spec…... Full story

Yahoo Finance • 12 days ago

ImmunityBio Inc. (IBRX) Receives FDA Warning Letter Over Cancer Therapy Claims in Advertisement

ImmunityBio Inc. (NASDAQ:IBRX) is one of the best high growth healthcare stocks to buy now. On March 24, the FDA posted a warning letter to its site, stating that its Office of Prescription Drug Promotion “reviewed the promotional communic... Full story

Yahoo Finance • 13 days ago

INVESTOR NOTICE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RGRD Law

SAN DIEGO, March 30, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities between January 19, 2026 and March 24, 2025, both dates... Full story

Yahoo Finance • 14 days ago

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX

NEW YORK, March 29, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January... Full story

Yahoo Finance • 16 days ago

ImmunityBio, Inc. (IBRX) Faces Securities Class Action Amid FDA Warning Regarding Unsupported Cancer Treatment Claims, $2 Billion Market Capitalization Wiped Out – Hagens Berman

SAN FRANCISCO, March 27, 2026 (GLOBE NEWSWIRE) -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19,... Full story

Yahoo Finance • 17 days ago

IBRX INVESTOR ALERT: ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit – RGRD Law

SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the ImmunityBio class action lawsuit seeks to represent purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities... Full story